Clinical trial · Interventional
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation
A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation
NCT02283424CI-TRIAL-00015995unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene mutation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms, Therapy-Associated | Neoplasm | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemotherapy (Carboplatin and Docetaxel) | Drug | — | UNRESOLVED |
| Icotinib | Drug | Icotinib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- chemotherapy
- description
- Carboplatin,350mg/m2,1/3weeks Docetaxel,75mg/m2,1/3weeks
- interventionNames
- Drug: Icotinib
- Drug: chemotherapy (Carboplatin and Docetaxel)
- type
- EXPERIMENTAL
- label
- Icotinib
- description
- Icotinib, 125mg,3/D,2years
- interventionNames
- Drug: Icotinib
- Drug: chemotherapy (Carboplatin and Docetaxel)
Primary outcomes (1)
- measure
- Recurrence-free Survival
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 18-75 years old * Lung adenocarcinoma patients with epidermal growth factor receptor gene mutation,stage I-IIIB after surgery * The patients' Eastern Cooperative Oncology Group scores are ≤ 0-2 Exclusion Criteria: * Mismatch conditions above * Have used other anti-cancer therapy drug before the trial and may influence the outcome
References
Publications (0)
Data not yet available
No reference posted for this study.